BioCryst (BCRX) Stock Forecast & Price Target

Compare

2,658 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCRX Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

BioCryst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$21.50

▲(188.59% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $21.50 with a high forecast of $32.00 and a low forecast of $13.00. The average price target represents a 188.59% change from the last price of $7.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","33":"$33","12.75":"$12.75","19.5":"$19.5","26.25":"$26.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.75,19.5,26.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.8,9.661538461538461,11.523076923076923,13.384615384615383,15.246153846153845,17.107692307692307,18.96923076923077,20.83076923076923,22.692307692307693,24.553846153846155,26.415384615384617,28.27692307692308,30.138461538461538,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.8,8.853846153846154,9.907692307692308,10.961538461538462,12.015384615384615,13.069230769230769,14.123076923076923,15.176923076923078,16.23076923076923,17.284615384615385,18.338461538461537,19.392307692307693,20.446153846153848,{"y":21.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.8,8.2,8.6,9,9.4,9.8,10.2,10.6,11,11.4,11.8,12.2,12.600000000000001,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$21.50

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$17

Buy

128.19%

Upside

Initiated

02/18/26

Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)

Brian Abrahams

RBC Capital

$14→$13

Buy

74.50%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Steris (NYSE: STE), Arcellx Inc (NASDAQ: ACLX) and BioCryst (NASDAQ: BCRX)

Tazeen Ahmad

Bank of America Securities

$15

Buy

101.34%

Upside

Reiterated

01/30/26

Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)

Laura Chico

Wedbush

$21

Buy

181.88%

Upside

Reiterated

01/13/26

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

Serge Belanger

Needham

$18

Buy

141.61%

Upside

Reiterated

01/12/26

BioCryst: Sustained Orladeyo Momentum, Disciplined Financials, and Pipeline Upside Support Buy Rating

Steven Seedhouse

Cantor Fitzgerald

$26

Buy

248.99%

Upside

Reiterated

01/12/26

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

Stacy Ku

TD Cowen

$30

Buy

302.68%

Upside

Reiterated

12/23/25

TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)

Andrew Fein

H.C. Wainwright

$30→$32

Buy

329.53%

Upside

Reiterated

12/15/25

BioCryst's Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating

Jonathan Wolleben

Citizens JMP

$27→$25

Buy

235.57%

Upside

Reiterated

11/05/25

BioCryst price target lowered to $25 from $27 at Citizens JMPBioCryst price target lowered to $25 from $27 at Citizens JMP

Gena Wang

Barclays

$11→$9

Hold

20.81%

Upside

Reiterated

11/03/25

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

Maury Raycroft

Jefferies

$15

Buy

101.34%

Upside

Reiterated

10/14/25

BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability

Jessica Fye

J.P. Morgan

$10→$13

Buy

74.50%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$17

Buy

128.19%

Upside

Initiated

02/18/26

Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)

Brian Abrahams

RBC Capital

$14→$13

Buy

74.50%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Steris (NYSE: STE), Arcellx Inc (NASDAQ: ACLX) and BioCryst (NASDAQ: BCRX)

Tazeen Ahmad

Bank of America Securities

$15

Buy

101.34%

Upside

Reiterated

01/30/26

Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)

Laura Chico

Wedbush

$21

Buy

181.88%

Upside

Reiterated

01/13/26

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

Serge Belanger

Needham

$18

Buy

141.61%

Upside

Reiterated

01/12/26

BioCryst: Sustained Orladeyo Momentum, Disciplined Financials, and Pipeline Upside Support Buy Rating

Steven Seedhouse

Cantor Fitzgerald

$26

Buy

248.99%

Upside

Reiterated

01/12/26

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

Stacy Ku

TD Cowen

$30

Buy

302.68%

Upside

Reiterated

12/23/25

TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)

Andrew Fein

H.C. Wainwright

$30→$32

Buy

329.53%

Upside

Reiterated

12/15/25

BioCryst's Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating

Jonathan Wolleben

Citizens JMP

$27→$25

Buy

235.57%

Upside

Reiterated

11/05/25

BioCryst price target lowered to $25 from $27 at Citizens JMPBioCryst price target lowered to $25 from $27 at Citizens JMP

Gena Wang

Barclays

$11→$9

Hold

20.81%

Upside

Reiterated

11/03/25

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

Maury Raycroft

Jefferies

$15

Buy

101.34%

Upside

Reiterated

10/14/25

BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability

Jessica Fye

J.P. Morgan

$10→$13

Buy

74.50%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+17.26%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.26% per trade.

1 Year

Jessica FyeJ.P. Morgan

Success Rate

6/12 ratings generated profit

Average Return

+19.02%

reiterated a buy rating 10 months ago

Copying Jessica Fye's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.02% per trade.

2 Years

xxx

Success Rate

7/20 ratings generated profit

Average Return

-6.60%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -6.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCRX has received 21 Buy Ratings, 31 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 21.50.

Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is $0.05 with a range of $0.01 to $0.12. The previous quarter’s EPS was $0.06. BCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $151.32M with a range of $146.74M to $157.72M. The previous quarter’s sales results were $159.40M. BCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 21.50.

What is BCRX’s upside potential, based on the analysts’ average price target?

Biocryst Pharmaceuticals has 188.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCRX a Buy, Sell or Hold?

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Biocryst Pharmaceuticals’s price target?

The average price target for Biocryst Pharmaceuticals is 21.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $13.00. The average price target represents 188.59% Increase from the current price of $7.45.

What do analysts say about Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of BCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioCryst (BCRX) Stock Forecast & Price Target

BCRX Analyst Ratings

BCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioCryst

BCRX Analyst Recommendation Trends

BCRX Financial Forecast

BCRX Earnings Forecast

BCRX Sales Forecast

BCRX Stock Forecast FAQ

Detailed List of Analyst Forecasts